Analysts expect that Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Rating) will post ($0.20) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Gemini Therapeutics’ earnings. Gemini Therapeutics reported earnings per share of ($0.59) during the same quarter last year, which suggests a positive year over year […]
Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Rating) major shareholder Braden Michael Leonard acquired 191,769 shares of the firm’s stock in a transaction that occurred on Wednesday, April 13th. The stock was bought at an average cost of $1.52 per share, with a total value of $291,488.88. Following the completion of the transaction, the insider now […]